Extended survival in a patient with leptomeningeal disease related to EGFR exon 19 deletion metastatic non-small cell lung cancer: a case report.

IF 0.5 Q4 ONCOLOGY

International Cancer Conference Journal Pub Date : 2025-05-31 eCollection Date: 2025-07-01 DOI:10.1007/s13691-025-00777-8

Ehab Harahsheh, Vinicius Ernani, Skyler J Taylor, Kliment Donev, Maciej M Mrugala

{"title":"Extended survival in a patient with leptomeningeal disease related to EGFR exon 19 deletion metastatic non-small cell lung cancer: a case report.","authors":"Ehab Harahsheh, Vinicius Ernani, Skyler J Taylor, Kliment Donev, Maciej M Mrugala","doi":"10.1007/s13691-025-00777-8","DOIUrl":null,"url":null,"abstract":"<p><p>We report a case of a 60-year-old female diagnosed with epidermal growth factor receptor (EGFR) exon 19-mutant non-small cell lung cancer (NSCLC). She developed leptomeningeal disease (LMD) about 2 years after her initial cancer diagnosis and experienced multiple subsequent relapses of her leptomeningeal carcinomatosis with parenchymal brain metastases. She currently is alive with excellent performance status at 82 months since the LMD diagnosis. Treatment has consisted of different conventional and experimental EGFR targeted therapies along with intrathecal chemotherapy. This report, to the best of our knowledge, represents the longest overall survival (OS) of LMD reported in patients with EGFR-mutant NSCLC and suggests that leveraging different mechanisms of action to target EGFR mutation in a sequential fashion with multidisciplinary teams' involvement can potentially help control the LMD and prolong the OS in this patient population.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"335-339"},"PeriodicalIF":0.5000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226433/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Cancer Conference Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13691-025-00777-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

We report a case of a 60-year-old female diagnosed with epidermal growth factor receptor (EGFR) exon 19-mutant non-small cell lung cancer (NSCLC). She developed leptomeningeal disease (LMD) about 2 years after her initial cancer diagnosis and experienced multiple subsequent relapses of her leptomeningeal carcinomatosis with parenchymal brain metastases. She currently is alive with excellent performance status at 82 months since the LMD diagnosis. Treatment has consisted of different conventional and experimental EGFR targeted therapies along with intrathecal chemotherapy. This report, to the best of our knowledge, represents the longest overall survival (OS) of LMD reported in patients with EGFR-mutant NSCLC and suggests that leveraging different mechanisms of action to target EGFR mutation in a sequential fashion with multidisciplinary teams' involvement can potentially help control the LMD and prolong the OS in this patient population.

查看原文本刊更多论文

与EGFR外显子19缺失相关的轻脑膜疾病转移性非小细胞肺癌患者的延长生存期：1例报告

我们报告一例60岁女性被诊断为表皮生长因子受体（EGFR）外显子19突变的非小细胞肺癌（NSCLC）。她在最初的癌症诊断后大约2年患上了轻脑膜病（LMD），并经历了多次轻脑膜癌复发并脑实质转移。自LMD诊断82个月以来，她目前还活着，表现良好。治疗包括不同的常规和实验性EGFR靶向治疗以及鞘内化疗。据我们所知，该报告代表了EGFR突变NSCLC患者中LMD的最长总生存期（OS），并表明在多学科团队的参与下，利用不同的作用机制以顺序的方式靶向EGFR突变，可能有助于控制LMD并延长该患者群体的OS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Cancer Conference Journal ONCOLOGY-

自引率

14.30%

发文量

期刊介绍： This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports on all types of cancer - In particular, welcomes molecularly analyzed cancer cases - The Official Publication of the Japan Society of Clinical Oncology (JSCO)